GLP-1 RA HCP Site
a Major adverse CV events (MACE)=CV death, nonfatal MI, or nonfatal stroke. b SUSTAIN 7 included 0.5 mg and 1.0 mg doses for Ozempic ® and 0.75 mg and 1.5 mg doses for Trulicity ®. c Weight change was a secondary endpoint in clinical trials. d Results apply to Ozempic ® plus standard of care vs standard of care alone in SUSTAIN 6 trial for patients with T2D and established CVD.
Actived: 7 days ago
Ozempic® (semaglutide) injection 0.5 mg or 1 mg Clinical
Patients: A total of 397 adult patients inadequately controlled on basal insulin with or without metformin were randomized to once-weekly Ozempic ® 0.5 mg (n=132), Ozempic ® 1 mg (n=131), or placebo (n=133). Randomization was stratified according to A1C at screening. Patients with A1C ≤8% at screening reduced the insulin dose by 20% at the
Ozempic® (semaglutide) injection 0.5 mg or 1 mg Ozempic
More than double the weight reduction for each dose comparison vs Trulicity ®1. Results are from a 40-week, randomized, open-label, active-controlled trial in 1201 adult patients with type 2 diabetes comparing Ozempic ® 0.5 mg to Trulicity ® 0.75 mg and Ozempic ® 1 mg to Trulicity ® 1.5 mg. 1.
Ozempic® (semaglutide) injection 0.5 mg or 1 mg Consider
Consider why. a GLP-1 RA therapy once-weekly Ozempic ® should be the. first injectable. for most patients. See why it’s time to think of prescribing a GLP-1 RA therapy prior to basal insulin for your appropriate adult patients with type 2 diabetes. This program is sponsored by Novo Nordisk. Dr Craig Wierum and Lisa Coco, NP, received a fee